Loading…

Loading grant details…

Completed NON-SBIR/STTR RPGS NIH (US)

The Pdx1-recruited Swi/Snf chromatin remodeling complex regulates endocrine cell expansion and differentiation in vivo

$1.19M USD

Funder NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
Recipient Organization Indiana University Indianapolis
Country United States
Start Date Jan 01, 2021
End Date Dec 31, 2022
Duration 729 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 10321296
Grant Description

PROJECT SUMMARY/ABSTRACT Pancreatic β-cells within the islets of Langerhans are required for glucose-stimulated insulin secretion and glucose homeostasis. Dysfunctional β-cell activity and identity results in diabetes mellitus (DM), a growing disease affecting millions of Americans, thus creating an enormous fiscal and health burden. Strategies to

improve outcomes for the mounting number of diabetic patients and the possibility to replace destroyed and dysfunctional β-cell mass requires a deep understanding of the complex programs that coordinate proper islet formation. Developing upon existing knowledge of how islet enriched transcription factors (TFs) coordinate

signals that direct islet cell development will allow us to understand how such programs can be targeted for β- cell replacement therapies. Pdx1, one of the most important TFs in the pancreas and developing islet, has been shown to recruit a diverse set of coregulators which could potentially modulate its activity. This proposal is focused around how the

Pdx1 recruited ATP-dependent Swi/Snf chromatin remodeling complex modulates Pdx1 transcriptional activity in the developing islet. Previous work by the PI’s group revealed a critical role for Pdx1:Swi/Snf function in the developing pancreas and the mature β-cell. Preliminary studies thus far have shown that conditional removal of

one of the core Swi/Snf ATPase subunits (through Cre-LoxP technology) from developing endocrine progenitor cells results in glucose intolerance, ad libitum fed hyperglycemia and reduced serum insulin levels in mutant animals postnatally. This proposal will test the hypothesis that Pdx1-recruited Swi/Snf chromatin remodeling

activities control chromatin accessibility and gene expression programs essential for endocrine progenitor cell expansion and postnatal islet cell function. In Aim 1, the PI will use this novel transgenic animal model to determine islet cell function, expression of islet cell maturation markers, hormone secretion and hormone cell

mass in adult pancreata. In Aim 2, embryonic tissues from mutant animals will be used to determine changes in endocrine progenitor cell mass and hormone cell proliferation/apoptosis. The mechanistic actions of Swi/Snf on directing chromatin accessibility and gene expression programs in endocrine progenitors will be determined by

ATAC-Seq, RNA-Seq and ChIP-qPCR analyses on flow-sorted Swi/Snf-deficient endocrine precursors. My extensive experience studying transcription factor coregulatory complexes and our available in vivo reagents make my lab uniquely suited to accomplish these Aims. Mechanisms defined by these studies will

uncover key processes and unique gene expression signatures dependent on chromatin remodeling during endocrine development, which will provide instrumental knowledge to researchers developing new molecular targets and cell-based therapies to combat diabetes. Importantly, this proposal has also been designed to

generate data and resources that the applicant will utilize in an R01 application defining how dysregulated enhancer function from Type 2 diabetic (T2D) islet donors are influenced by altered Pdx1:Swi/Snf actions.

All Grantees

Indiana University Indianapolis

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant